A2a/D2 receptor interactions are not observed in COS-7 cells transiently transfected with dopamine D2 and adenosine

P Snaprud1, P Gerwins, M G Caron

  • 1Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.

Biochemical Pharmacology
|November 29, 1994
PubMed

Insights

Transiently transfected dopamine D2 and adenosine A2a receptors in COS-7 cells exhibit normal binding but poor signaling. These receptors do not directly interact, suggesting other factors mediate previously observed A2a-D2 receptor interactions.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cell Biology

Background:

  • Dopamine D2 receptors and adenosine A2a receptors are G protein-coupled receptors involved in various physiological processes.
  • Previous studies suggested potential interactions between D2 and A2a receptors in certain cellular contexts.
  • COS-7 cells are a common cell line for transient transfection and receptor expression studies.

Purpose of the Study:

  • To investigate the expression, binding properties, and signaling capacity of rat D2 and dog A2a receptors transiently transfected into COS-7 cells.
  • To determine if co-expression of D2 and A2a receptors in COS-7 cells leads to altered binding characteristics or functional interactions.
  • To elucidate the coupling of these receptors to adenylyl cyclase in a heterologous expression system.

Main Methods:

  • Transient transfection of COS-7 cells with rat D2 and dog A2a receptor constructs using the DEAE-dextran method.
  • Radioligand binding assays using [3H]raclopride or [3H]-N-propyl-apomorphine for D2 receptors and [3H]-CGS 21680 for A2a receptors.
  • Measurement of cyclic AMP (cAMP) accumulation in response to receptor agonists to assess adenylyl cyclase activity.

Main Results:

  • Transfected COS-7 cells expressed functional D2 and A2a receptors with high affinity binding properties.
  • Adenosine receptor agonists stimulated cAMP accumulation, primarily via endogenous A2b receptors, not the transfected A2a receptors.
  • Dopamine did not affect cAMP levels, and A2a selective agonists did not alter D2 receptor binding characteristics, even in co-transfected cells.
  • Despite expressing functional receptors, adenylyl cyclase coupling was poor for both D2 and A2a receptors in COS-7 cells.

Conclusions:

  • Transiently expressed D2 and A2a receptors in COS-7 cells possess normal binding but exhibit impaired coupling to adenylyl cyclase.
  • The absence of observed interactions between D2 and A2a receptors in this system suggests that direct physical interaction between the receptor proteins may not be the primary mechanism for their previously reported interplay.
  • These findings highlight the importance of cellular context and potential accessory factors in mediating receptor-receptor interactions and signaling.

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...